Biological predictors of pharmacological therapy in anxiety disorders

Dialogues in Clinical Neuroscience

Volumn 17, Issue 3, 2015, Pages 305-317

  Maron, Eduard ^a,b,c   Nutt, David ^c  

^a North Estonia Medical Centre   (Estonia)

^b UNIVERSITY OF TARTU   (Estonia)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Antidepressant; Anxiety disorder; Biomarker; Brain imaging; Gene; Treatment predictor

Indexed keywords

ANXIOLYTIC AGENT; BIOLOGICAL MARKER;

ANXIETY DISORDER; ARTICLE; BLOOD ANALYSIS; BLOOD LEVEL; DRUG THERAPY; GENETICS; HEREDITY; HUMAN; META ANALYSIS (TOPIC); NEUROIMAGING; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; ANXIETY DISORDERS; BLOOD; BRAIN; DRUG EFFECTS; PATHOLOGY; PATHOPHYSIOLOGY; PREDICTIVE VALUE;

ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; BIOMARKERS; BRAIN; HUMANS; NEUROIMAGING; PREDICTIVE VALUE OF TESTS;

EID: 84945252958     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (122)

1. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:617-627.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th edition. Washington, DC: American Psychiatric Association; 2013.
3. Farb DH, Ratner MH. Targeting the modulation of neural circuitry for the treatment of anxiety disorders. Pharmacol Rev. 2014;66:1002-1032.
4. Mendlowicz MV, Stein MB Quality of life in individuals with anxiety disorders. Am J Psychiatry. 2000;157:669-682.
5. Rice DP, Miller LS. Health economics and cost implications of anxiety and other mental disorders in the United States. Br J Psychiatry. 1998;34(suppl):4-9.
6. Whooly MA, Simon GE. Managing depression in medical outpatients. N Engl J Med. 2000;343:1942-1950.
7. Markowitz JS, Weissman MM, Ouellette R, Lish JD, Klerman GL. Quality of life in panic disorder. Arch Gen Psychiatry. 1989;46:984-992.
8. DuPont RL, Rice DP, Miller LS, Shiraki SS, Rowland CR, Harwood HJ. Economic costs of anxiety disorders. Anxiety. 1996;2:167-172.
9. Scott KA, Hoban AE, Clarke G, Moloney GM, Dinan TG, Cryan JF. Thinking small: towards microRNA-based therapeutics for anxiety disorders. Expert Opin Investig Drugs. 2015;8:1-14.
10. Noyes R Jr, Crowe RR, Harris EL, Hamra BJ, McChesney CM, Chaudhry DR. Relationship between panic disorder and agoraphobia. A family study. Arch Gen Psychiatry. 1986;43:227-232.
11. Faravelli C, Paterniti S, Scarpato A. 5-year prospective, naturalistic follow-up study of panic disorder. Compr Psychiatry. 1995;36:271-277.
12. Ravindran LN, Stein MB. The pharmacologic treatment of anxiety disorders: a review of progress. J Clin Psychiatry. 2010;71:839-854.
13. Wang SM, Pae CU. How much to worry about the FDA warning in the use of citalopram? Expert Rev Neurother. 2013;13:883-886.
14. Argyropoulos SV, Nutt DJ. The use of benzodiazepines in anxiety and other disorders. Eur Neuropsychopharmacol. 1999;6:S407-S412.
15. Leuchter AF, Cook IA, Hamilton SP, et al. Biomarkers to predict antidepressant response. Curr Psychiatry Rep. 2010;12:553-562.
16. Fu CH, Steiner H, Costafreda SG. Predictive neural biomarkers of clinical response in depression: a meta-analysis of functional and structural neuroimaging studies of pharmacological and psychological therapies. Neurobiol Dis. 2013;52:75-83.
17. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354:1243-1252.
18. Rush AJ, Warden D, Wisniewski SR, et al. STAR*D: revising conventional wisdom. CNS Drugs. 2009;23:627-647.
19. Rush AJ. Limitations in efficacy of antidepressant monotherapy. J Clin Psychiatry. 2007;68:8-10.
20. Keitner GI, Ryan CE, Miller IW, Norman WH. Recovery and major depression: factors associated with twelve-month outcome. Am J Psychiatry. 1992;149:93-99.
21. Warden D, Trivedi MH, Wisniewski SR, et al. Predictors of attrition during initial (citalopram) treatment for depression: a STAR*D report. Am J Psychiatry. 2007;164:1189-1197.
22. Olfson M, Marcus SC, Tedeschi M, Wan GJ. Continuity of antidepressant treatment for adults with depression in the United States. Am J Psychiatry. 2006;163:101-108.
23. Bagby RM, Ryder AG, Cristi C. Psychosocial and clinical predictors of response to pharmacotherapy for depression. J Psychiatry Neurosci. 2002;27:250-257.
24. Joyce PR, Mulder RT, Cloninger CR. Temperament predicts clomipramine and desipramine response in major depression. J Affect Disord. 1994;30:35-46.
25. Lerer B, Macciardi F. Pharmacogenetics of antidepressant and mood-stabilizing drugs: a review of candidate-gene studies and future research directions. Int J Neuropsychopharmacol. 2002;5:255-275.
26. Szadoczky E, Rozsa S, Zambori J, Füredi J. Predictors for 2-year outcome of major depressive episode. J Affect Disord. 2004;83:49-57.
27. Labermaier C, Masana M, Müller MB. Biomarkers predicting antidepressant treatment response: how can we advance the field? Dis Markers. 2013;35:23-31.
28. Niciu MJ, Mathews DC, Nugent AC, et al. Developing biomarkers in mood disorders research through the use of rapid-acting antidepressants. Depress Anxiety. 2014;31:297-307.
29. Koolschijn PC, van Haren NE, Lensvelt-Mulders GJ, Hulshoff Pol HE, Kahn RS. Brain volume abnormalities in major depressive disorder: a meta-analysis of magnetic resonance imaging studies. Hum Brain Mapp. 2009;30:3719-3735.
30. Hajek T, Kozeny J, Kopecek M, Alda M, Höschl C. Reduced subgenual cingulate volumes in mood disorders: a meta-analysis. J Psychiatry Neurosci. 2008;33:91-99.
31. McKinnon M, Yucel K, Nazarov A, MacQueen GM. A meta-analysis examining clinical predictors of hippocampal volume in patients with major depressive disorder. J Psychiatry Neurosci. 2009;34:41-54.
32. MacQueen GM, Yucel K, Taylor VH, Macdonald K, Joffe R. Posterior hippocampal volumes are associated with remission rates in patients with major depressive disorder. Biol Psychiatry. 2008;64:880-888.
33. Vakili K, Pillay SS, Lafer B, et al. Hippocampal volume in primary unipolar major depression: a magnetic resonance imaging study. Biol Psychiatry. 2000;47:1087-1090.
34. Costafreda SG, Chu C, Ashburner J, Fu CH. Prognostic and diagnostic potential of the structural neuroanatomy of depression. PLoS One. 2009;4:e6353.
35. Mayberg HS, Brannan SK, Mahurin RK, et al. Cingulate function in depression: a potential predictor of treatment response. Neuroreport. 1997;8:1057-1061.
36. Alexopoulos GS, Kiosses DN, Choi SJ, Murphy CF, Lim KO. Frontal white matter microstructure and treatment response of late-life depression: a preliminary study. Am J Psychiatry. 2002;159:1929-1932.
37. Alexopoulos GS, Murphy CF, Gunning-Dixon FM, et al. Microstructural white matter abnormalities and remission of geriatric depression. Am J Psychiatry. 2008;165:238-244.
38. Choi J, Jeong B, Rohan ML, Polcari AM, Teicher MH. Preliminary evidence for white matter tract abnormalities in young adults exposed to parental verbal abuse. Biol Psychiatry. 2009;65:227-234.
39. Alexopoulos GS, Murphy CF, Gunning-Dixon FM, et al. Serotonin transporter polymorphisms, microstructural white matter abnormalities and remission of geriatric depression. J Affect Disord. 2009;119:132-141.
40. Levy-Gigi E, Szabó C, Kelemen O, Kéri S. Association among clinical response, hippocampal volume, and FKBP5 gene expression in individuals with posttraumatic stress disorder receiving cognitive behavioral therapy. Biol Psychiatry. 2013;74:793-800.
41. Bryant RA, Felmingham K, Whitford TJ, et al. Rostral anterior cingulate volume predicts treatment response to cognitive-behavioural therapy for posttraumatic stress disorder. J Psychiatry Neurosci. 2008;33:142-146.
42. Dickie EW, Brunet A, Akerib V, Armony JL. Anterior cingulate cortical thickness is a stable predictor of recovery from post-traumatic stress disorder. Psychol Med. 2013;43:645-653.
43. Lai CH, Wu YT. Changes in regional homogeneity of parieto-temporal regions in panic disorder patients who achieved remission with antidepressant treatment. J Affect Disord. 2013;151:709-714.
44. Lai CH, Wu YT, Yu PL, Yuan W. Improvements in white matter microstructural integrity of right uncinate fasciculus and left fronto-occipital fasciculus of remitted first-episode medication-naïve panic disorder patients. J Affect Disord. 2013;150:330-336.
45. Lai CH, Hsu YY. A subtle grey-matter increase in first-episode, drugnaïve major depressive disorder with panic disorder after 6 weeks' duloxetine therapy. Int J Neuropsychopharmacol. 2011;14:225-235.
46. Hoexter MQ, Dougherty DD, Shavitt RG, et al. Differential prefrontal gray matter correlates of treatment response to fluoxetine or cognitive-behavioral therapy in obsessive-compulsive disorder. Eur Neuropsychopharmacol. 2013;23:569-580.
47. Banks GP, Mikell CB, Youngerman BE, et al. Neuroanatomical characteristics associated with response to dorsal anterior cingulotomy for obsessive-compulsive disorder. JAMA Psychiatry. 2015;72:127-135.
48. Anand A, Li Y, Wang Y, et al. Antidepressant effect on connectivity of the mood-regulating circuit: an FMRI study. Neuropsychopharmacology. 2005;30:1334-1344.
49. Fu CH, Williams SC, Cleare AJ, et al. Attenuation of the neural response to sad faces in major depression by antidepressant treatment: a prospective, event-related functional magnetic resonance imaging study. Arch Gen Psychiatry. 2004;61:877-889.
50. Sheline YI, Barch DM, Donnelly JM, Ollinger JM, Snyder AZ, Mintun MA. Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: an fMRI study. Biol Psychiatry. 2001;50:651-658.
51. Fu CH, Williams SC, Cleare AJ, Scott J, et al. Neural responses to sad facial expressions in major depression following cognitive behavioral therapy. Biol Psychiatry. 2008;64:505-512.
52. Chen CH, Suckling J, Ooi C, et al. Functional coupling of the amygdala in depressed patients treated with antidepressant medication. Neuropsychopharmacology. 2008;33:1909-1918.
53. Anand A, Li Y, Wang Y, Gardner K, Lowe MJ. Reciprocal effects of antidepressant treatment on activity and connectivity of the mood regulating circuit: an FMRI study. J Neuropsychiatry Clin Neurosci. 2007;19:274-282.
54. Hahn T, Kircher T, Straube B, et al. Predicting treatment response to cognitive behavioral therapy in panic disorder with agoraphobia by integrating local neural information. JAMA Psychiatry. 2015;72:68-74.
55. Lueken U, Straube B, Konrad C, et al. Neural substrates of treatment response to cognitive-behavioral therapy in panic disorder with agoraphobia. Am J Psychiatry. 2013;170:1345-1355.
56. Lueken U, Straube B, Wittchen HU, et al. Therapygenetics: anterior cingulate cortex-amygdala coupling is associated with 5-HTTLPR and treatment response in panic disorder with agoraphobia. J Neural Transm. 2015;122:135-144.
57. Reinecke A, Thilo K, Filippini N, Croft A, Harmer CJ. Predicting rapid response to cognitive-behavioural treatment for panic disorder: the role of hippocampus, insula, and dorsolateral prefrontal cortex. Behav Res Ther. 2014;62:120-128.
58. Ball TM, Stein MB, Ramsawh HJ, Campbell-Sills L, Paulus MP. Singlesubject anxiety treatment outcome prediction using functional neuroimaging. Neuropsychopharmacology. 2014;39:1254-1261.
59. Whalen PJ, Johnstone T, Somerville LH, et al. A functional magnetic resonance imaging predictor of treatment response to venlafaxine in generalized anxiety disorder. Biol Psychiatry. 2008;63:858-863.
60. Nitschke JB, Sarinopoulos I, Oathes DJ, et al. Anticipatory activation in the amygdala and anterior cingulate in generalized anxiety disorder and prediction of treatment response. Am J Psychiatry. 2009;166:302-310.
61. Pantazatos SP, Talati A, Schneier FR, Hirsch J. Reduced anterior temporal and hippocampal functional connectivity during face processing discriminates individuals with social anxiety disorder from healthy controls and panic disorder, and increases following treatment. Neuropsychopharmacology. 2014;39:425-434.
62. Klumpp H, Keutmann MK, Fitzgerald DA, Shankman SA, Phan KL. Resting state amygdala-prefrontal connectivity predicts symptom change after cognitive behavioral therapy in generalized social anxiety disorder. Biol Mood Anxiety Disord. 2014;4:14.
63. Doehrmann O, Ghosh SS, Polli FE, et al. Predicting treatment response in social anxiety disorder from functional magnetic resonance imaging. JAMA Psychiatry. 2013;70:87-97.
64. Klumpp H, Fitzgerald DA, Phan KL. Neural predictors and mechanisms of cognitive behavioral therapy on threat processing in social anxiety disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2013;45:83-91.
65. Zhu H, Qiu C, Meng Y, et al. Altered spontaneous neuronal activity in chronic posttraumatic stress disorder patients before and after a 12-week paroxetine treatment. J Affect Disord. 2015;174:257-264.
66. van Rooij SJ, Geuze E, Kennis M, Rademaker AR, Vink M. Neural correlates of inhibition and contextual cue processing related to treatment response in PTSD. Neuropsychopharmacology. 2015;40:667-675.
67. Shin DJ, Jung WH, He Y, et al. The effects of pharmacological treatment on functional brain connectome in obsessive-compulsive disorder. Biol Psychiatry. 2014;75:606-614.
68. Sanematsu H, Nakao T, Yoshiura T, et al. Predictors of treatment response to fluvoxamine in obsessive-compulsive disorder: an fMRI study. J Psychiatr Res. 2010;44:193-200.
69. Deckersbach T, Dougherty DD, Rauch SL. Functional imaging of mood and anxiety disorders. J Neuroimaging. 2006;16:1-10.
70. Kugaya A, Sanacora G, Staley JK, et al. Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors. Biol Psychiatry. 2004;56:497-502.
71. Lanzenberger R, Kranz GS, Haeusler D, et al. Prediction of SSRI treatment response in major depression based on serotonin transporter interplay between median raphe nucleus and projection areas. Neuroimage. 2012;63:874-881.
72. Brockmann H, Zobel A, Joe A, et al. The value of HMPAO SPECT in predicting treatment response to citalopram in patients with major depression. Psychiatry Res. 2009;173:107-112.
73. Milak MS, Parsey RV, Lee L, et al. Pretreatment regional brain glucose uptake in the midbrain on PET may predict remission from a major depressive episode after three months of treatment. Psychiatry Res. 2009;173:63-70.
74. Parsey RV, Olvet DM, Oquendo MA, Huang YY, Ogden RT, Mann JJ. Higher 5-HT1A receptor binding potential during a major depressive episode predicts poor treatment response: preliminary data from a naturalistic study. Neuropsychopharmacology. 2006;31:1745-1749.
75. Kang EH, Park JE, Lee KH, Cho YS, Kim JJ, Yu BH. Regional brain metabolism and treatment response in panic disorder patients: an [18F]FDGPET study. Neuropsychobiology. 2012;66:106-111.
76. Faria V, Ahs F, Appel L, et al. Amygdala-frontal couplings characterizing SSRI and placebo response in social anxiety disorder. Int J Neuropsychopharmacol. 2014;17:1149-1157.
77. Van der Linden G, van Heerden B, Warwick J, et al. Functional brain imaging and pharmacotherapy in social phobia: single photon emission computed tomography before and after treatment with the selective serotonin reuptake inhibitor citalopram. Prog Neuropsychopharmacol Biol Psychiatry. 2000;24:419-438.
78. Evans KC, Simon NM, Dougherty DD, et al. A PET study of tiagabine treatment implicates ventral medial prefrontal cortex in generalized social anxiety disorder. Neuropsychopharmacology. 2009;34:390-398.
79. Wen SL, Cheng MH, Cheng MF, Yue JH, Wang H. Pharmacotherapy response and regional cerebral blood flow characteristics in patients with obsessive-compulsive disorder. Behav Brain Funct. 2013;9:31.
80. Ho Pian KL, van Megen HJ, Ramsey NF, et al. Decreased thalamic blood flow in obsessive-compulsive disorder patients responding to fluvoxamine. Psychiatry Res. 2005;138:89-97.
81. Rauch SL, Shin LM, Dougherty DD, Alpert NM, Fischman AJ, Jenike MA. Predictors of fluvoxamine response in contamination-related obsessive compulsive disorder: a PET symptom provocation study. Neuropsychopharmacology. 2002;27:782-791.
82. Carey PD, Warwick J, Niehaus DJ, et al. Single photon emission computed tomography (SPECT) of anxiety disorders before and after treatment with citalopram. BMC Psychiatry. 2004;4:30.
83. Seedat S, Warwick J, van Heerden B, et al. Single photon emission computed tomography in posttraumatic stress disorder before and after treatment with a selective serotonin reuptake inhibitor. J Affect Disord. 2004;80:45-53.
84. Yamanishi T, Nakaaki S, Omori IM, et al. Changes after behavior therapy among responsive and nonresponsive patients with obsessive-compulsive disorder. Psychiatry Res. 2009;172:242-250.
85. Seo HJ, Choi YH, Chung YA, Rho W, Chae JH. Changes in cerebral blood flow after cognitive behavior therapy in patients with panic disorder: a SPECT study. Neuropsychiatr Dis Treat. 2014;10:661-669.
86. Lindauer RJ, Booij J, Habraken JB, et al. Effects of psychotherapy on regional cerebral blood flow during trauma imagery in patients with post-traumatic stress disorder: a randomized clinical trial. Psychol Med. 2008;38:543-554.
87. Maron E, Nutt D, Shlik J. Neuroimaging of serotonin system in anxiety disorders. Curr Pharm Des. 2012;18:5699-5708.
88. Stengler-Wenzke K, Müller U, Barthel H, Angermeyer MC, Sabri O, Hesse S. Serotonin transporter imaging with [123I]beta-CIT SPECT before and after one year of citalopram treatment of obsessive-compulsive disorder. Neuropsychobiology. 2006;53:40-45.
89. Warwick JM, Carey PD, Cassimjee N, et al. Dopamine transporter binding in social anxiety disorder: the effect of treatment with escitalopram. Metab Brain Dis. 2012;27:151-158.
90. Grimm S, Luborzewski A, Schubert F, et al. Region-specific glutamate changes in patients with unipolar depression. J Psychiatr Res. 2012;46:1059-1065.
91. Olbrich S, Arns M. EEG biomarkers in major depressive disorder: discriminative power and prediction of treatment response. Int Rev Psychiatry. 2013;25:604-618.
92. Cornwell BR, Salvadore G, Furey M, et al. Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression. Biol Psychiatry. 2012;72:555-561.
93. Li CT, Chen LF, Tu PC, Wang SJ, Chen MH, Su TP, et al. Impaired prefronto-thalamic functional connectivity as a key feature of treatmentresistant depression: a combined MEG, PET and rTMS study. PLoS One. 2013;8:e70089.
94. Pickar D, Rubinow K. Pharmacogenomics of psychiatric disorders. Trends Pharmacol Sci. 2001;22:75-83.
95. Serretti A, Artioli P, Quartesan R. Pharmacogenetics in the treatment of depression: pharmacodynamic studies. Pharmacogenet Genomics. 2005;15:61-67.
96. Fabbri C, Di Girolamo G, Serretti A. Pharmacogenetics of antidepressant drugs: an update after almost 20 years of research. Am J Med Genet B Neuropsychiatr Genet. 2013;162B:487-520.
97. Porcelli S, Drago A, Fabbri C, Gibiino S, Calati R, Serretti A. Pharmacogenetics of antidepressant response. J Psychiatry Neurosci. 2011;36:87-113.
98. Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry. 2010;15:473-500.
99. Perna G, Favaron E, Di Bella D, Bussi R, Bellodi L. Antipanic efficacy of paroxetine and polymorphism within the promoter of the serotonin transporter gene. Neuropsychopharmacology. 2005;30:2230-2235.
100. Yevtushenko OO, Oros MM, Reynolds GP. Early response to selective serotonin reuptake inhibitors in panic disorder is associated with a functional 5-HT1A receptor gene polymorphism. J Affect Disord. 2010;123:308-311.
101. Mushtaq D, Ali A, Margoob MA, Murtaza I, Andrade C. Association between serotonin transporter gene promoter-region polymorphism and 4- and 12-week treatment response to sertraline in posttraumatic stress disorder. J Affect Disord. 2012;136:955-962.
102. Stein MB, Seedat S, Gelernter J. Serotonin transporter gene promoter polymorphism predicts SSRI response in generalized social anxiety disorder. Psychopharmacology (Berl). 2006;187:68-72.
103. Andersson E, Rück C, Lavebratt C, Hedman et al. Genetic polymorphisms in monoamine systems and outcome of cognitive behavior therapy for social anxiety disorder. PLoS One. 2013;8:e79015.
104. Stein MB, Keshaviah A, Haddad SA, et al. Influence of RGS2 on sertraline treatment for social anxiety disorder. Neuropsychopharmacology. 2014;39:1340-1346.
105. Cooper AJ, Narasimhan S, Rickels K, Lohoff FW. Genetic polymorphisms in the PACAP and PAC1 receptor genes and treatment response to venlafaxine XR in generalized anxiety disorder. Psychiatry Res. 2013;210:1299-1300.
106. Cooper AJ, Rickels K, Lohoff FW. Association analysis between the A118G polymorphism in the OPRM1 gene and treatment response to venlafaxine XR in generalized anxiety disorder. Hum Psychopharmacol. 2013;28:258-262.
107. Lohoff FW, Narasimhan S, Rickels K. Interaction between polymorphisms in serotonin transporter (SLC6A4) and serotonin receptor 2A (HTR2A) genes predict treatment response to venlafaxine XR in generalized anxiety disorder. Pharmacogenomics J. 2013;13:464-469.
108. Narasimhan S, Aquino TD, Multani PK, Rickels K, Lohoff FW. Variation in the catechol-O-methyltransferase (COMT) gene and treatment response to venlafaxine XR in generalized anxiety disorder. Psychiatry Res. 2012;198:112-115.
109. Lohoff FW, Aquino TD, Narasimhan S, Multani PK, Etemad B, Rickels K. Serotonin receptor 2A (HTR2A) gene polymorphism predicts treatment response to venlafaxine XR in generalized anxiety disorder. Pharmacogenomics J. 2013;13:21-26.
110. Narasimhan S, Aquino TD, Hodge R, Rickels K, Lohoff FW. Association analysis between the Val66Met polymorphism in the brain-derived neurotrophic factor (BDNF) gene and treatment response to venlafaxine XR in generalized anxiety disorder. Neurosci Lett. 2011;503:200-202.
111. Perlis RH, Fijal B, Dharia S, Houston JP. Pharmacogenetic investigation of response to duloxetine treatment in generalized anxiety disorder. Pharmacogenomics J. 2013;13:280-285.
112. Zai G, Brandl EJ, Müller DJ, Richter MA, Kennedy JL. Pharmacogenetics of antidepressant treatment in obsessive-compulsive disorder: an update and implications for clinicians. Pharmacogenomics. 2014;15:1147-1157.
113. Maron E, Pettai K, Tammiste A, et al. Are there specific genes underlying treatment resistance in depression? New evidence from genome-wide analysis. Paper presented at: 22nd ECNP Congress 2009. (S.13.01.)
114. Tammiste A, Jiang T, Fischer K, et al. Whole-exome sequencing identifies a polymorphism in the BMP5 gene associated with SSRI treatment response in major depression. J Psychopharmacol. 2013;27:915-920.
115. Lehrner A, Yehuda R. Biomarkers of PTSD: military applications and considerations. Eur J Psychotraumatol. 2014;14:5.
116. Olff M, de Vries GJ, Güzelcan Y, Assies J, Gersons BP. Changes in cortisol and DHEA plasma levels after psychotherapy for PTSD. Psychoneuroendocrinology. 2007;32:619-626.
117. Yehuda R, Bierer LM, Sarapas C, Makotkine I, Andrew R, Seckl JR. Cortisol metabolic predictors of response to psychotherapy for symptoms of PTSD in survivors of the World Trade Center attacks on September 11, 2001. Psychoneuroendocrinology. 2009;34:1304-1313.
118. Delorme R, Chabane N, Callebert J, et al. Platelet serotonergic predictors of clinical improvement in obsessive compulsive disorder. J Clin Psychopharmacol. 2004;24:18-23.
119. Lee IS, Kim KJ, Kang EH, Yu BH. beta-adrenoceptor affinity as a biological predictor of treatment response to paroxetine in patients with acute panic disorder. J Affect Disord. 2008;110:156-160.
120. Kobayashi K, Shimizu E, Hashimoto K, et al. Serum brain-derived neurotrophic factor (BDNF) levels in patients with panic disorder: as a biological predictor of response to group cognitive behavioral therapy. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29:658-663.
121. Brandl EJ, Tiwari AK, Zhou X, et al. Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder. Pharmacogenomics J. 2014;14:176-181.
122. Qin H, Samuels JF, Wang Y, Zhu Y, et al. Whole-genome association analysis of treatment response in obsessive-compulsive disorder. Mol Psychiatry. In press.